Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
Director departure
Appointed director
SELLAS Life Sciences Group, Inc. (SLS) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 8-K Quarterly results
08/10/2023 8-K Quarterly results
Docs: "SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2023 Financial Results"
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
06/01/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "SELLAS Life Sciences Group, Inc. Transcript of Virtual Panel Discussion"
05/11/2023 8-K Quarterly results
Docs: "SELLAS Life Sciences Provides Business Update and Reports First Quarter 2023 Financial Results"
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/17/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/16/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/16/2023 8-K Quarterly results
Docs: "SELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business Update"
03/16/2023 10-K Annual Report for the period ended December 31, 2022
03/10/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
03/01/2023 8-K Quarterly results
02/24/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
02/24/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "EXHIBIT 1,1",
"COMMON STOCK PURCHASE WARRANT SELLAS Life Sciences Group, Inc. Warrant Shares: _______ Issue Date: February ___, 2023 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date and on or prior to 5:00 p.m. on February __, 2028 but not thereafter, to subscribe for and purchase from SELLAS Life Sciences Group, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not otherwise defined herein shall have the me...",
"SELLAS Life Sciences Group, Inc. 7 Times Square, Suite 2503 New York, New York 10036",
"Printing and Mailing Expenses",
"Investor Contact"
02/23/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
02/23/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
02/06/2023 8-K Quarterly results
12/13/2022 8-K Quarterly results
11/15/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
09/16/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Corporate Presentation for September 15, 2022 Webinar",
"SELLAS Life Sciences Group, Inc. Transcript of Investor Webinar"
08/16/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
08/11/2022 10-Q Quarterly Report for the period ended June 30, 2022
06/09/2022 8-K Quarterly results
05/12/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/12/2022 8-K Quarterly results
05/12/2022 10-Q Quarterly Report for the period ended March 31, 2022
04/25/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/25/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/06/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "SELLAS Life Sciences Group, Inc. — Business Update and First Quarter 2022 Highlights Call, April 6, 2022 CORPORATE PARTICIPANTS"
04/01/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy